Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer
Crossref DOI link: https://doi.org/10.1007/s00280-015-2855-z
Published Online: 2015-10-27
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wu, Zheng
Gabrielson, Andrew
Hwang, Jimmy J.
Pishvaian, Michael J.
Weiner, Louis M.
Zhuang, Tingting
Ley, Lisa
Marshall, John L.
He, Aiwu Ruth
Funding for this research was provided by:
American Cancer Society (11825-MRSG-10-068-01-TBE)
Text and Data Mining valid from 2015-10-27